List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/485119/publications.pdf Version: 2024-02-01



ΙΔΝΙΔ ΜΑΡΟ

#	Article	IF	CITATIONS
1	TBP, PPIA, YWHAZ and EF1A1 Are the Most Stably Expressed Genes during Osteogenic Differentiation. International Journal of Molecular Sciences, 2022, 23, 4257.	1.8	4
2	Glucocorticoid Receptor Regulates TNFSF11 Transcription by Binding to Glucocorticoid Responsive Element in TNFSF11 Proximal Promoter Region. International Journal of Molecular Sciences, 2021, 22, 1054.	1.8	4
3	COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects. International Journal of Environmental Research and Public Health, 2021, 18, 7859.	1.2	49
4	Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis. Endocrine Practice, 2021, 27, 941-947.	1.1	7
5	Treatment of osteoporosis with teriparatide: The Slovenian experience. Open Medicine (Poland), 2021, 16, 1544-1551.	0.6	2
6	Roles of Non-Canonical Wnt Signalling Pathways in Bone Biology. International Journal of Molecular Sciences, 2021, 22, 10840.	1.8	35
7	Perspective of the GEMSTONE Consortium on Current and Future Approaches to Functional Validation for Skeletal Genetic Disease Using Cellular, Molecular and Animal-Modeling Techniques. Frontiers in Endocrinology, 2021, 12, 731217.	1.5	12
8	Plasma levels of miR-30d-5p are decreased in regularly exercising postmenopausal women. Menopause, 2020, 27, 319-325.	0.8	6
9	Increased Exhaustion of the Subchondral Bone-Derived Mesenchymal Stem/ Stromal Cells in Primary Versus Dysplastic Osteoarthritis. Stem Cell Reviews and Reports, 2020, 16, 742-754.	1.7	15
10	Trace elements and APOE polymorphisms in pregnant women and their new-borns. Environment International, 2020, 143, 105626.	4.8	8
11	Comprehensive analysis of skeletal muscle- and bone-derived mesenchymal stem/stromal cells in patients with osteoarthritis and femoral neck fracture. Stem Cell Research and Therapy, 2020, 11, 146.	2.4	25
12	Mercury speciation in prenatal exposure in Slovenian and Croatian population – PHIME study. Environmental Research, 2019, 177, 108627.	3.7	11
13	Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis. Experimental and Molecular Medicine, 2019, 51, 1-16.	3.2	10
14	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics, 2019, 20, 643-657.	0.6	65
15	4th ESPT Conference: pharmacogenomics and personalized medicine– research progress and clinical implementation. Pharmacogenomics, 2019, 20, 1063-1069.	0.6	1
16	Skeletal-muscle-derived mesenchymal stem/stromal cells from patients with osteoarthritis show superior biological properties compared to bone-derived cells. Stem Cell Research, 2019, 38, 101465.	0.3	25
17	Association of FTO gene variant (rs8050136) with type 2 diabetes and markers of obesity, glycaemic control and inflammation. Journal of Medical Biochemistry, 2019, 38, 153-163.	0.7	27
18	The role of artichoke leaf tincture (<i>Cynara scolymus</i>) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. Pharmaceutical Biology, 2018, 56, 138-144.	1.3	13

#	Article	IF	CITATIONS
19	Mesenchymal Stem Cells in the Musculoskeletal System: From Animal Models to Human Tissue Regeneration?. Stem Cell Reviews and Reports, 2018, 14, 346-369.	5.6	53
20	Increased Plasma Cathepsin S at the Time of Percutaneous Transluminal Angioplasty is Associated with 6-Months' Restenosis of the Femoropopliteal Artery. Journal of Medical Biochemistry, 2018, 37, 54-61.	0.7	2
21	Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. Annals of the Rheumatic Diseases, 2018, 77, 378-385.	0.5	21
22	A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: the VEGF Consortium. Clinical Chemistry and Laboratory Medicine, 2018, 56, 83-86.	1.4	1
23	VEGF-A is associated with early degenerative changes in cartilage and subchondral bone. Growth Factors, 2018, 36, 263-273.	0.5	14
24	Human Skeletal Muscle-Derived Mesenchymal Stem/Stromal Cell Isolation and Growth Kinetics Analysis. Methods in Molecular Biology, 2018, 2045, 119-129.	0.4	10
25	Epigenetic enzymes influenced by oxidative stress and hypoxia mimetic in osteoblasts are differentially expressed in patients with osteoporosis and osteoarthritis. Scientific Reports, 2018, 8, 16215.	1.6	31
26	Epigenetic Mechanisms in Osteoporosis. , 2018, , 365-388.		3
27	Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease. Angiology, 2018, 69, 861-870.	0.8	26
28	Genetic effects on bone health. Current Opinion in Clinical Nutrition and Metabolic Care, 2018, 21, 233-239.	1.3	4
29	Personalized laboratory medicine: a patient-centered future approach. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1981-1991.	1.4	33
30	The use of ELM and MnM servers for the prediction of RANK function in osteoclast formation. IFMBE Proceedings, 2017, , 372-378.	0.2	0
31	Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study. Vascular Pharmacology, 2017, 99, 45-52.	1.0	3
32	Prenatal mercury exposure, neurodevelopment and apolipoprotein E genetic polymorphism. Environmental Research, 2017, 152, 375-385.	3.7	53
33	Bone microRNAs and Ageing. Current Pharmaceutical Biotechnology, 2017, 18, 210-220.	0.9	18
34	The impact of gene polymorphisms in angiotensin receptor 1 and aldosterone synthase in peritoneal dialysis patients. Clinical Nephrology, 2017, 88, 73-77.	0.4	1
35	The "Rise–Peak–Fall―Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats. Journal of Cardiovascular Pharmacology, 2016, 68, 74-80.	0.8	2
36	MiR-148a the epigenetic regulator of bone homeostasis is increased in plasma of osteoporotic postmenopausal women. Wiener Klinische Wochenschrift, 2016, 128, 519-526.	1.0	63

#	Article	IF	CITATIONS
37	P4Âmedicine and osteoporosis: aÂsystematic review. Wiener Klinische Wochenschrift, 2016, 128, 480-491.	1.0	8
38	Risk factors for symptomatic osteonecrosis in childhood ALL: A retrospective study of a Slovenian pediatric ALL population between 1970 and 2004. Experimental and Therapeutic Medicine, 2016, 12, 840-846.	0.8	2
39	The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA / Plejotropni Efekti Atorvastatina Kod Pacijenata Sa Stabilnom Anginom: Dokazi Dobijeni Analizom VeliÄine I Raspodele Subfrakcija Lipoproteina Velike Custine L Plazmatske mRna Journal of Medical Biochemistry, 2015, 34, 314-322	0.7	1
40	<scp>ADRA</scp> 2A is involved in neuroâ€endocrine regulation of bone resorption. Journal of Cellular and Molecular Medicine, 2015, 19, 1520-1529.	1.6	19
41	Childhood Osteoporosis and Presentation of Two Cases with Osteogenesis Imperfecta Type V / Osteoporoza V OtroÅ _i ki Dobi in Predstavitev Dveh Bolnikov Z Osteogenesis Imperfecta Tipa V. Zdravstveno Varstvo, 2015, 54, 119-125.	0.6	2
42	Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Clinical Chemistry and Laboratory Medicine, 2015, 53, 981-8.	1.4	18
43	Bone remodeling during orthodontic tooth movement in rats with type 2 diabetes. American Journal of Orthodontics and Dentofacial Orthopedics, 2015, 148, 1017-1025.	0.8	20
44	Hypoxia mimetic deferoxamine influences the expression of histone acetylation- and DNA methylation-associated genes in osteoblasts. Connective Tissue Research, 2015, 56, 228-235.	1.1	18
45	Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Drug Metabolism and Personalized Therapy, 2015, 30, 121-128.	0.3	9
46	Atorvastatin treatment increases plasma bilirubin but not <i>HMOX1</i> expression in stable angina patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 382-389.	0.6	9
47	Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma. Clinica Chimica Acta, 2015, 439, 128-136.	0.5	5
48	Association of LPIN1 gene variations with markers of metabolic syndrome in population from Bosnia and Herzegovina. Medicinski Glasnik, 2015, 12, 113-21.	0.3	3
49	The many faces of estrogen signaling. Biochemia Medica, 2014, 24, 329-342.	1.2	296
50	Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients. Journal of Atherosclerosis and Thrombosis, 2014, 21, 868-877.	0.9	7
51	Effects of the PPARG Gene Polymorphisms on Markers of Obesity and the Metabolic Syndrome in Bosnian Subjects. Journal of Medical Biochemistry, 2014, 33, 323-332.	0.7	6
52	Increased phosphatidylethanolamine N-methyltransferase gene expression in non-small-cell lung cancer tissue predicts shorter patient survival. Oncology Letters, 2014, 7, 2175-2179.	0.8	18
53	Epigenetic mechanisms in bone. Clinical Chemistry and Laboratory Medicine, 2014, 52, 589-608.	1.4	75
54	Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway. Drug Metabolism and Drug Interactions, 2014, 29, 111-114.	0.3	6

#	Article	IF	CITATIONS
55	Influence of trypsinization and alternative procedures for cell preparation before RNA extraction on RNA integrity. Analytical Biochemistry, 2014, 463, 38-44.	1.1	16
56	The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig. European Journal of Pharmacology, 2014, 743, 31-36.	1.7	7
57	Inverse correlation of carotid intima-media thickness with raloxifene serum levels in osteoporosis. Wiener Klinische Wochenschrift, 2014, 126, 403-408.	1.0	2
58	Preparation of reference material for UGT1A1 (TA)n polymorphism genotyping. Clinica Chimica Acta, 2014, 435, 24-28.	0.5	3
59	Triglyceride metabolism in bone tissue is associated with osteoblast and osteoclast differentiation: a gene expression study. Journal of Bone and Mineral Metabolism, 2013, 31, 512-519.	1.3	30
60	Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: Pleiotropic evidence from plasma mRNA analyses. Clinical Biochemistry, 2013, 46, 1526-1531.	0.8	7
61	Treatment With Low-dose Atorvastatin, Losartan, and Their Combination Increases Expression of Vasoactive-Related Genes in Rat Aortas. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 177-183.	1.0	12
62	Lipoprotein lipase in non-small cell lung cancer tissue is highly expressed in a subpopulation of tumor-associated macrophages. Pathology Research and Practice, 2013, 209, 516-520.	1.0	20
63	Monitoring of imatinib targeted delivery in human leukocytes. European Journal of Pharmaceutical Sciences, 2013, 50, 123-129.	1.9	2
64	Osteoporosis pharmacogenomics: recent insights and future perspectives. Pharmacogenomics, 2013, 14, 451-454.	0.6	4
65	Research Highlights: Highlights from the latest pharmacogenomic genome-wide association studies. Pharmacogenomics, 2013, 14, 357-360.	0.6	0
66	Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts. Biochemia Medica, 2013, 23, 43-63.	1.2	131
67	Osteoarthritic versus osteoporotic bone and intraâ€skeletal variations in normal bone: Evaluation with µCT and bone histomorphometry. Journal of Orthopaedic Research, 2013, 31, 1059-1066.	1.2	21
68	BMD Values and <i>GSTM3</i> Gene Polymorphisms in Combination with <i>GSTT1/GSTM1</i> Genes: A Genetic Association Study in Slovenian Elderly. Gerontology, 2012, 58, 238-248.	1.4	4
69	Interleukin-11± gene variants influence bone mineral density and the risk of osteoporotic hip fractures in elderly Slovenian people. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1379-85.	1.4	12
70	Antioxidant enzymes GSR, SOD1, SOD2, and CAT gene variants and bone mineral density values in postmenopausal women. Menopause, 2012, 19, 368-376.	0.8	31
71	Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Translational Research, 2012, 160, 298-308.	2.2	28
72	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 2012, 44, 491-501.	9.4	1,100

#	Article	IF	CITATIONS
73	Testing GSTP1 genotypes and haplotypes interactions in Slovenian post-/pre-menopausal women: Novel involvement of glutathione S-transferases in bone remodeling process. Maturitas, 2012, 71, 180-187.	1.0	11
74	Assessment of gene-by-sex interaction effect on bone mineral density. Journal of Bone and Mineral Research, 2012, 27, 2051-2064.	3.1	47
75	Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene. Journal of Translational Medicine, 2012, 10, 76.	1.8	24
76	Arsenic Trioxide (ATO) Influences the Gene Expression of Metallothioneins in Human Glioblastoma Cells. Biological Trace Element Research, 2012, 149, 331-339.	1.9	23
77	The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. Journal of Biomedical Science, 2012, 19, 28.	2.6	60
78	Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population. Biochemia Medica, 2012, 22, 76-85.	1.2	6
79	TNFRSF11B gene polymorphisms 1181G>C and 245T>G as well as haplotype CT influence bone mineral density in postmenopausal women. Maturitas, 2011, 69, 263-267.	1.0	25
80	Expression of 11β-hydroxysteroid dehydrogenase type 1 in visceral and subcutaneous adipose tissues of patients with polycystic ovary syndrome is associated with adiposity. Journal of Steroid Biochemistry and Molecular Biology, 2011, 123, 127-132.	1.2	19
81	â~'1227C>T polymorphism in the pleiotrophin gene promoter influences bone mineral density in postmenopausal women. Molecular Genetics and Metabolism, 2011, 103, 76-80.	0.5	11
82	PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: A pilot study. Clinical Biochemistry, 2011, 44, 1085-1089.	0.8	8
83	Opposite Effects of <i>GSTM1</i> – and <i>GSTT1</i> – Gene Deletion Variants on Bone Mineral Density. Disease Markers, 2011, 31, 279-287.	0.6	6
84	Association of NAT2 Polymorphisms with Type 2 Diabetes in a Population from Bosnia and Herzegovina. Archives of Medical Research, 2011, 42, 311-317.	1.5	11
85	Osteoblastogenesis and Adipogenesis Are Higher in Osteoarthritic than in Osteoporotic Bone Tissue. Archives of Medical Research, 2011, 42, 392-397.	1.5	33
86	Optimization of High-Resolution Melting Analysis for Simultaneous Genotyping of Two 11β-Hydroxysteroid Dehydrogenase Type 1 Gene Polymorphisms. Genetic Testing and Molecular Biomarkers, 2011, 15, 43-49.	0.3	4
87	Effect of cetirizine, a histamine (H1) receptor antagonist, on bone modeling during orthodontic tooth movement in rats. American Journal of Orthodontics and Dentofacial Orthopedics, 2011, 139, e323-e329.	0.8	30
88	CTSS activation coexists with CD40 activation in human atheroma: Evidence from plasma mRNA analysis. Clinical Biochemistry, 2011, 44, 438-440.	0.8	8
89	New insights into adipose tissue dysfunction in insulin resistance. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1925-35.	1.4	68
90	Increased DAPK1 but decreased CCL2 plasma levels of nucleic acids in patients with stable angina. Biochemia Medica, 2011, 21, 291-296.	1.2	2

#	Article	IF	CITATIONS
91	Optimisation of methods for quantifying plasma mRNA levels from genes responsible for coronary artery plaque development and destabilization. Medicinski Glasnik, 2011, 8, 90-6.	0.3	1
92	Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis. Clinical Biochemistry, 2010, 43, 1427-1430.	0.8	6
93	The Antioxidant Enzyme <i>GPX1</i> Gene Polymorphisms Are Associated with Low BMD and Increased Bone Turnover Markers. Disease Markers, 2010, 29, 71-80.	0.6	24
94	Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosnian Journal of Basic Medical Sciences, 2010, 10, 287-291.	0.6	20
95	Gene–gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 102-106.	1.2	29
96	Xbal polymorphism of the estrogen receptor alpha gene influences the effect of raloxifene on the endothelial function. Maturitas, 2010, 67, 84-90.	1.0	6
97	A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts. Bone, 2010, 46, 72-80.	1.4	66
98	The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. Journal of Molecular Endocrinology, 2009, 42, 239-247.	1.1	54
99	Increased Lipoprotein Lipase Activity in Non-small Cell Lung Cancer Tissue Predicts Shorter Patient Survival. Archives of Medical Research, 2009, 40, 364-368.	1.5	21
100	Analysis of Association of LRP5, LRP6, SOST, DKK1, and CTNNB1 Genes with Bone Mineral Density in a Slovenian Population. Calcified Tissue International, 2009, 85, 501-506.	1.5	24
101	Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology, 2009, 67, 437-444.	1.1	32
102	Increased Apolipoprotein E Gene Expression and Protein Concentration in Lung Cancer Tissue Do Not Contribute to the Clinical Assessment of Non-small Cell Lung Cancer Patients. Archives of Medical Research, 2008, 39, 663-667.	1.5	17
103	Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome European Journal of Endocrinology, 2008, 158, 793-801.	1.9	37
104	Decreased lipin 1β expression in visceral adipose tissue is associated with insulin resistance in polycystic ovary syndrome. European Journal of Endocrinology, 2008, 159, 833-839.	1.9	20
105	Tumour necrosis factor superfamily member 11 gene promoter polymorphisms modulate promoter activity and influence bone mineral density in postmenopausal women with osteoporosis. Journal of Molecular Endocrinology, 2008, 40, 273-279.	1.1	28
106	Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women. Menopause, 2008, 15, 369-373.	0.8	14
107	7. Pharmacogenetics of Drug Receptors. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2008, 19, 48-53.	0.7	3
108	Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1014-8.	1.4	24

#	Article	IF	CITATIONS
109	Molecular mechanisms of insulin resistance and associated diseases. Clinica Chimica Acta, 2007, 375, 20-35.	0.5	240
110	Exonic, but not intronic polymorphisms of ESR1 gene might influence the hypolipemic effect of raloxifene. Journal of Steroid Biochemistry and Molecular Biology, 2007, 104, 22-26.	1.2	11
111	Development and validation of a liquid chromatography–tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 855, 220-227.	1.2	36
112	LIPOPROTEIN LIPASE ACTIVITY AND GENE EXPRESSION IN LUNG CANCER AND IN ADJACENT NONCANCER LUNG TISSUE. Experimental Lung Research, 2007, 33, 217-225.	0.5	23
113	Expression of bone resorption genes in osteoarthritis and in osteoporosis. Journal of Bone and Mineral Metabolism, 2007, 25, 219-225.	1.3	137
114	Genetic Succeptibility to Metabolic Syndrome. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2007, 18, 7-14.	0.7	1
115	Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women. Maturitas, 2006, 55, 219-226.	1.0	27
116	Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?. Nephrology Dialysis Transplantation, 2005, 20, 566-570.	0.4	37
117	Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. Maturitas, 2005, 51, 270-279.	1.0	64
118	Vitamin D receptor gene polymorphism and bone metabolism during low-dose oral contraceptive use in young women. Contraception, 2003, 67, 33-37.	0.8	11
119	Frequencies of Q188R and N314D Mutations and IVS5-24G>A Intron Variation in the Galactose-1-Phosphate Uridyl Transferase (GALT) Gene in the Slovenian Population. Clinical Chemistry and Laboratory Medicine, 2002, 40, 1109-13.	1.4	8
120	Increased Levels of Osteoprotegerin in Hemodialysis Patients. Clinical Chemistry and Laboratory Medicine, 2002, 40, 1019-23.	1.4	39
121	No major effect of estrogen receptor beta gene Rsal polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. Journal of Steroid Biochemistry and Molecular Biology, 2002, 81, 147-152.	1.2	46
122	Codon 325 sequence polymorphism of the estrogen receptor α gene and bone mineral density in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology, 2001, 78, 15-20.	1.2	22
123	Optimization of Single-Stranded Conformation Polymorphism (SSCP) Analysis for Screening for the Estrogen Receptor-1± Gene Polymorphism P325P. Clinical Chemistry and Laboratory Medicine, 2001, 39, 612-4.	1.4	0
124	Molecular impact of glutathione peroxidases in antioxidant processes. Biochemia Medica, 0, , 162-174.	1.2	30